Technology
Health
Pharmaceutical
Axsome Therapeutics
$13.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$13.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.24 (-1.81%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell AXSM and other stocks, options, ETFs, and crypto commission-free!
About
Axsome Therapeutics, Inc. Common Stock, also called Axsome Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Read More Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Employees
29
Headquarters
New York, New York
Founded
2012
Market Cap
391.13M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
726.33K
High Today
$13.46
Low Today
$12.51
Open Price
$13.35
Volume
633.23K
52 Week High
$14.24
52 Week Low
$1.94
Collections
Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2015 IPO
US
News
MarketWatchMar 22
Harry Boxer: 3 biotech stocks with momentum
Biotech stocks dominate our list of top charts to watch today. Axsome Therapeutics Inc. AXSM, -1.81% (AXSM) jumped $1.23 to $13.24 on 1.9 million shares Thursday. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. The stock is a little overbought in the short term — down only once in the last three weeks — but momentum is strong for a move toward $16. Support is at the March 19 low in...
Seeking AlphaMar 14
Axsome Therapeutics, Inc. 2018 Q4 - Results - Earnings Call Slides
The following slide deck was published by Axsome Therapeutics, Inc. in conjunction with their 2018 Q4 earnings call. 1 41 Click to enlarge Notes:...
Associated PressMar 14
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2018. “In 2018, we advanced our clinical programs and significantly expanded our CNS pipeline through the addition of new internally generated product...
Price Paid on Robinhood
54% Higher
Right Now
52 Week Low
$1.94
Average Price Paid
$8.45
52 Week High
$14.24
Earnings
-$0.34
-$0.29
-$0.24
-$0.19
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.30 per share
Actual
-$0.32 per share